21.53 USD
-0.22 (-1.01%)
21.3 USD
-0.23 (-1.07%)
We assign a fundamental rating of 3 out of 10 to SRPT. SRPT was compared to 531 industry peers in the Biotechnology industry. Both the profitability and financial health of SRPT have multiple concerns. SRPT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SRPT had negative earnings in the past year.
SRPT had a negative operating cash flow in the past year.
In the past 5 years SRPT reported 4 times negative net income.
In the past 5 years SRPT reported 4 times negative operating cash flow.
1.2 Ratios
SRPT has a Return On Assets of -7.77%. This is amongst the best in the industry. SRPT outperforms 84.75% of its industry peers.
SRPT has a better Return On Equity (-20.57%) than 83.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROIC | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SRPT (76.25%) is better than 83.99% of its industry peers.
SRPT's Gross Margin has been stable in the last couple of years.
SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
2. Health
2.1 Basic Checks
SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRPT has more shares outstanding
SRPT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SRPT has an improved debt to assets ratio.
2.2 Solvency
SRPT has an Altman-Z score of 0.00. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
SRPT has a Altman-Z score (0.00) which is in line with its industry peers.
A Debt/Equity ratio of 0.78 indicates that SRPT is somewhat dependend on debt financing.
SRPT has a worse Debt to Equity ratio (0.78) than 74.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0 |
ROIC/WACCN/A
WACC7.38%
2.3 Liquidity
A Current Ratio of 2.95 indicates that SRPT has no problem at all paying its short term obligations.
The Current ratio of SRPT (2.95) is worse than 65.72% of its industry peers.
SRPT has a Quick Ratio of 1.79. This is a normal value and indicates that SRPT is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.79, SRPT is doing worse than 77.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -197.60%.
The Revenue has grown by 47.15% in the past year. This is a very strong growth!
SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.94% yearly.
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
3.2 Future
Based on estimates for the next years, SRPT will show a small growth in Earnings Per Share. The EPS will grow by 2.74% on average per year.
SRPT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.76% yearly.
EPS Next Y-337.39%
EPS Next 2Y7.13%
EPS Next 3Y-2.79%
EPS Next 5Y2.74%
Revenue Next Year13.41%
Revenue Next 2Y-8.28%
Revenue Next 3Y-7.62%
Revenue Next 5Y-5.76%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 8.23, the valuation of SRPT can be described as reasonable.
98.87% of the companies in the same industry are more expensive than SRPT, based on the Price/Forward Earnings ratio.
SRPT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.78.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.23 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as SRPT's earnings are expected to decrease with -2.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.13%
EPS Next 3Y-2.79%
5. Dividend
5.1 Amount
SRPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.53
-0.22 (-1.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.86%
Inst Owner Change1.91%
Ins Owners4.62%
Ins Owner Change10.75%
Market Cap2.26B
Revenue(TTM)2.41B
Net Income(TTM)-271.51M
Analysts68.24
Price Target29.96 (39.15%)
Short Float %18.02%
Short Ratio3.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)-9.22%
PT rev (3m)-10.78%
EPS NQ rev (1m)-23.36%
EPS NQ rev (3m)-74.49%
EPS NY rev (1m)-23.1%
EPS NY rev (3m)-13.5%
Revenue NQ rev (1m)3.26%
Revenue NQ rev (3m)6.8%
Revenue NY rev (1m)3.29%
Revenue NY rev (3m)4.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.23 | ||
| P/S | 0.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.71 | ||
| P/tB | 1.75 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.22
EYN/A
EPS(NY)2.62
Fwd EY12.15%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS23.03
BVpS12.6
TBVpS12.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% | ||
| FCFM | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score3
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 290.01% | ||
| Cap/Sales | 5.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 0 |
F-Score3
WACC7.38%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next Y-337.39%
EPS Next 2Y7.13%
EPS Next 3Y-2.79%
EPS Next 5Y2.74%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
Revenue Next Year13.41%
Revenue Next 2Y-8.28%
Revenue Next 3Y-7.62%
Revenue Next 5Y-5.76%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-278.15%
EBIT Next 3Y9.2%
EBIT Next 5Y11.92%
FCF growth 1Y36.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.58%
OCF growth 3YN/A
OCF growth 5YN/A
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRPT.
What is the valuation status of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.
How profitable is SAREPTA THERAPEUTICS INC (SRPT) stock?
SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.
What is the earnings growth outlook for SAREPTA THERAPEUTICS INC?
The Earnings per Share (EPS) of SAREPTA THERAPEUTICS INC (SRPT) is expected to decline by -337.39% in the next year.